Table 4.
Multivariate analysis for progression free survival by main groups
| Parameter | Level | N | Hazard Ratio | 95% Hazard Ratio Confidence Limits | p-value | |
|---|---|---|---|---|---|---|
| Race | AA w t(11;14) | 114 | 1.00 | 0.08 | ||
| AA w/o t(11;14) | 956 | 1.05 | 0.76 | 1.46 | 0.96 | |
| Whites w t(11;14) | 258 | 1.31 | 0.91 | 1.89 | 0.14 | |
| Whites w/o t(11;14) | 2157 | 1.01 | 0.73 | 1.39 | 0.77 | |
| Age at transplant | < 60 | 1773 | 1.00 | |||
| 60+ | 1712 | 1.06 | 0.95 | 1.19 | 0.28 | |
| Sex | Male | 1969 | 1.00 | |||
| Female | 1516 | 0.88 | 0.78 | 0.98 | 0.02 | |
| Karnofsky | ≥90 | 1872 | 1.00 | 0.04 | ||
| < 90 | 1531 | 1.19 | 1.14 | 1.02 | 0.02 | |
| Missing | 82 | 1.25 | 0.89 | 1.76 | 0.19 | |
| HCT-CI | 0 | 1074 | 1.00 | 0.03 | ||
| 1 | 548 | 1.23 | 1.04 | 1.46 | 0.02 | |
| 2 | 588 | 1.10 | 0.93 | 1.31 | 0.27 | |
| >2 | 1275 | 1.21 | 1.05 | 1.39 | 0.01 | |
| Lines of chemo | 1 | 2373 | 1.00 | <.0001 | ||
| >1 | 1079 | 1.46 | 1.29 | 1.64 | <.0001 | |
| Missing | 33 | 1.00 | 0.55 | 1.82 | 1.00 | |
| Disease status | PR/SD/PD/Relapse | 1888 | 1.00 | |||
| sCR/CR/VGPR | 1597 | 0.80 | 0.76 | 0.90 | 0.0001 | |
| Melphalan dose | MEL 140 | 990 | 1.00 | |||
| MEL 200 | 2495 | 0.86 | 0.76 | 0.97 | 0.02 | |
| Time from diagnosis to transplant | <6 | 1032 | 1.00 | 0.0014 | ||
| 6–12 | 1636 | 0.79 | 0.69 | 0.90 | 0.0005 | |
| > 12 | 817 | 0.91 | 0.77 | 1.06 | 0.23 | |
| Post-transplant rx | No | 911 | 1.00 | |||
| Yes | 2574 | 0.55 | 0.49 | 0.61 | <.0001 | |
AA; African Americans, w; with, w/o; without, HCT-CI; hematopoietic stem cell transplantation comorbidity index, PR; partial response, SD; stable disease, PD; progressive disease, sCR; stringent complete response, VGPR; very good partial response, MEL; melphalan